Profound Ai Icad Software To Evaluate
Food and Drug Administration (FDA). (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that ProFound AI ® Version 3.0 for Digital Breast Tomosynthesis (DBT) was cleared by the U.S. 3NASHUA, N.H., Ma(GLOBE NEWSWIRE) - iCAD, Inc. During BCAM, iCAD employees, like Thomas Carrington, are sharing what inspires them to contribute to our mission in the fight against breast cancer.Deep learning technology builds upon iCAD’s established leadership in mammography AIiCAD’s Breast Health Solutions suite also includes software to evaluate breast density, ProFound AI for 2D Mammography, and ProFound AI Risk, the world’s first and only clinical decision support tool that provides an accurate two-year breast cancer risk estimation that is truly personalized for each woman, based only on a screening mammogram.
Our third generation AI solution for DBT may afford physicians the ability to interpret an increasing amount of data in DBT cases and analyze each image to detect malignant lesions more efficiently and with even greater precision,” said Michael Klein, Chairman and CEO of iCAD. 1ProFound AI 2D is a computer-assisted detection and diagnosis Artificial Intelligence (AI) software device intended to be used by interpreting physicians while.“The FDA Clearance of ProFound AI Version 3.0 is yet another milestone that positions iCAD and our technology as vanguards in the cancer detection realm. 1 ProFound AI Version 3.0 also offers up to 40% faster processing on the new PowerLook platform.
Certainty of Finding and Case Scores are relative scores computed by the ProFound AI algorithm and represent its confidence that a detection or case is malignant. It became the first 3D tomosynthesis software using artificial intelligence (AI) to be FDA cleared in December 2018.Built with the latest in deep-learning technology, ProFound AI for DBT rapidly analyzes each tomosynthesis image, detecting malignant soft tissue densities. To increase sensitivity while simultaneously improving specificity is a huge performance achievement.”ProFound AI for DBT is a high-performance, deep-learning, workflow solution trained to detect malignant soft tissue densities and calcifications.
Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For more information, visit and Forward-Looking StatementsCertain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the benefits of the Company’s agreement with Solis and future prospects for the Company’s technology platforms and products. 2ICAD’s Breast Health Solutions suite also includes ProFound AI for 2D Mammography, ProFound AI Risk, the world’s first and only clinical decision support tool that provides an accurate two-year, breast cancer risk estimation that is truly personalized for each woman, based only on a screening mammogram, 3 and software to evaluate breast density.Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.
Standalone performance varies by vendor. Jeremy Feffer, LifeSci *iCAD data on file. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at and on the SEC’s website at. The Company is under no obligation to provide any updates to any information contained in this release. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements.
Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. Accessed via 3 Eriksson M, Czene K, Strand F, et al. Radiology: Artificial Intelligence. Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis.
0 kommentar(er)
